2023 World Conference on Lung Cancer (Posters)-EP08.03. S-1 and CDDP with Concurrent TRT Followed by Durvalumab in Elderly Population with Unresectable, LA-NSCLC in Japan: Post-hoc Analysis of SAMURAI

EP08.03. S-1 and CDDP with Concurrent TRT Followed by Durvalumab in Elderly Population with Unresectable, LA-NSCLC in Japan: Post-hoc Analysis of SAMURAI - PDF(Abstract)

Back to course

Pdf Summary

In this study, the researchers conducted a post-hoc analysis of the SAMURAI trial in Japan to evaluate the survival impact of S-1 and Cisplatin (SP) with concurrent thoracic radiation therapy (TRT) followed by durvalumab in elderly patients with unresectable, locally advanced non-small cell lung cancer (LA-NSCLC). The SAMURAI trial was a phase II study that showed positive results in terms of the primary endpoint. The researchers aimed to assess the survival impact of the treatment specifically in the elderly population.<br /><br />The study included 59 patients, of whom 24 were aged 70 or older. The transition rate from initial registration to durvalumab was 86.4% in the intent-to-treat population. The reasons for not proceeding to durvalumab were disease progression and adverse events. However, two of the patients who discontinued the protocol due to adverse events recovered and received durvalumab off-protocol.<br /><br />The post-hoc analysis showed no statistically significant difference in progression-free survival (PFS) and overall survival (OS) between the patients aged 70 or older and those younger than 70. The 12-month PFS and OS rates from initial registration were similar between the two groups. The median follow-up time was 21.9 months.<br /><br />From the second registration, both median PFS and OS were not reached in either group, and no significant difference was found between the age groups. The 12-month PFS and OS rates from the second registration were also similar between the two groups.<br /><br />The researchers concluded that SP-based chemoradiotherapy followed by durvalumab could be a potential treatment option for elderly patients with LA-NSCLC. However, further follow-up is necessary to evaluate the long-term outcomes of this treatment approach.<br /><br />Overall, this study provides insights into the efficacy of SP-based treatment followed by durvalumab in the elderly population with LA-NSCLC.

Asset Subtitle

Shigeru Tanzawa

Meta Tag

Speaker Shigeru Tanzawa

Topic Local-Regional NSCLC: Novel Therapies & Trials

Keywords

SAMURAI trial

S-1 and Cisplatin

thoracic radiation therapy

durvalumab

elderly patients

unresectable locally advanced non-small cell lung cancer

progression-free survival

overall survival

chemoradiotherapy

long-term outcomes